Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients

References

• Reiter A. Non-Hodgkin lymphoma in children and adolescent. Klin Padiatr. 2013;225:S87–S93.
   PubMed Web of Science ®Google Scholar
• Cairo MS, Pinkerton R. Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. Br J Haematol. 2016;173:507–530.
   PubMedGoogle Scholar
• Patte C. Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Haematol. 2002;15:695–711.
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-Cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 1999;94:3294–3306.
   PubMed Web of Science ®Google Scholar
• Tsurusawa M, Mori T, Kikuchi A, et al. Improved treatment results of children with B-cell non-Hodgkin lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. Pediatr Blood Cancer. 2014;61:1215–1221.
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Michon J, et al. The Societé Française d’Oncologie Pediatrique LMB89 Protocol: highly effective multiagent chemotherapy tailored to the tumour burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370–3379.
   PubMed Web of Science ®Google Scholar
• Woessman W, Seidermann K, Reiter K, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescent with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2004;105:948–958.
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Gerrard M, et al. Results of the randomised international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescent: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–2780.
   PubMed Web of Science ®Google Scholar
• Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141:840–847.
   PubMed Web of Science ®Google Scholar
• Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–2743.
   PubMed Web of Science ®Google Scholar
• Moleti ML, Al-Hadad SA, Al-Jadiry MF, et al. Treatment of children with B-Cell Non-Hodgkin Lymphoma in a low-income country. Pediatr Blood Cancer. 2011;56:560–567.
   PubMed Web of Science ®Google Scholar
• Abd El-Rahman H, Bedair RM. Treatment outcome of pediatric patients with Mature B Cell Lymphoma receiving FAB LMB96 Protocol at the National Cancer Institute, Cairo University. J Egypt Natl Canc Inst. 2010;22:201–208.
   PubMedGoogle Scholar
• Howard SC, Marinoni M, Castillo L, et al. Improving outcomes for children with cancer in low-income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)-Part I. Pediatr Blood Cancer. 2007;48:364–369.
   PubMed Web of Science ®Google Scholar
• Magrath I, Naresh KN, Advani S, et al. Report of an international network of cancer treatment and research workshop on non-Hodgkin's lymphoma in developing countries. Blood Cells Mol Dis. 2004;33:330–337.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Zaidi A, Badar F, et al. Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin’s lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country. Asia Pac J Clin Oncol. 2010;6:49–56.
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, Azim HA, Alizadeh H, et al. Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region. J Natl Compr Canc Netw. 2010;8:S29–S35.
   PubMedGoogle Scholar
• Béogo R, Nacro B, Ouédraogo D, et al. Endemic Burkitt lymphoma of maxillo facial region: results of induction treatment with Cyclophosphamide plus Methotrexate in West Africa. Pediatr Blood Cancer. 2011;56:1068–1070.
   PubMed Web of Science ®Google Scholar
• Frangoul H, Al-Jadiry MF, Shyr Y, et al. Shortage of chemotherapeutic agents in Iraq and outcome of childhood acute lymphocytic leukemia, 1990–2002. N Engl J Med. 2008;359:435–437.
   PubMed Web of Science ®Google Scholar
• Nouel A, Acquatella G, Insausti CI, et al. Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol. Pediatr Blood Cancer. 2004;43:580–586.
   PubMed Web of Science ®Google Scholar
• Belgaumi AF, Anas M, Siddiqui KS, et al. Risk-adapted stratification for optimally intensive treatment assignment of pediatric patients with non-Hodgkin lymphoma is an effective strategy in developing countries. Pediatr Blood Cancer. 2017;64:e26335.
   Web of Science ®Google Scholar
• Klumb CE, Schramm MT, De Resende LM, et al. Treatment of children with B-cell non-Hodgkin lymphoma in developing countries: the experience of a single center in Brazil. J Pediatr Hematol Oncol. 2004;26:462–468.
   PubMed Web of Science ®Google Scholar
• Harif M, Barsaoui S, Benchekroun S, et al. Treatment of B-cell lymphoma with LMB modified protocols in Africa – Report of the French – African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer. 2008;50:1138–1142.
   PubMed Web of Science ®Google Scholar
• Gross TG, Biondi A. Paediatric non-Hodgkin Lymphoma in low and middle income countries. Br J Haematol. 2016;173:651–654.
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112–2135.
   PubMed Web of Science ®Google Scholar
• Murphy SB. Classification, staging and results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7:332–339.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.
   PubMed Web of Science ®Google Scholar
• Simon R, Lee YJ. Nonparamentric condifence limits survival probabilities and median survival time. Cancer Trest Res. 1982;66:37–42.
   Google Scholar
• Hosmer DW, Lemeshow S. Applied logistic regression. New York, NY: Wiley; 1989.
   Google Scholar
• Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998–3003.
   PubMed Web of Science ®Google Scholar
• Wossman W, Schrappe M, Meyer U, et al. Incidence of tumor lysis syndrome in children with advanced stade Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 2003;82:160–165.
   PubMed Web of Science ®Google Scholar
• Galardy PJ, Hochberg J, Perkins SL, et al. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advances mature B-NHL: a Children’s Oncology Group Report. Br J Haematol. 2013;163:365–372.
   PubMed Web of Science ®Google Scholar
• Przybylski DJ, Reeves DJ. Impact of fluoroquinolone prophylaxis on documented infections in patients with febrile neutropenia. Infect Dis (Lond). 2018;50:395–398.
   PubMed Web of Science ®Google Scholar
• Al-Hadad SA, Al-Jadiry MF, Al-Darraji AF, et al. Reality of pediatric cancer in Iraq. J Pediatr Hematol Oncol. 2011;33(Suppl 2): S154–S156.
   PubMed Web of Science ®Google Scholar
• Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2013;27:1174–1177.
   PubMed Web of Science ®Google Scholar
• Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014;167:394–401.
   PubMed Web of Science ®Google Scholar
• Jaime-Perez JC, Gamboa-Alonso CM, Vàzquez-Mellado de Larracoechea A, et al. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma. Arch Med Res. 2015;46:454–461.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:2402–2411.
   PubMed Web of Science ®Google Scholar
• Samochatova EV, Maschan AA, Shelikhova LN, et al. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of multicenter study. J Pediatr Hematol Oncol. 2014;36:395–401.
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Auperin A, Pillon M, et al. results of the randomized intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab® efficacy in addition to standard LMB chemotherapy (CT) regimen. J of Clin Oncol. 2016;34. Abstract 10507.
   Web of Science ®Google Scholar
• De Zwart V, Gouw SC, Meyer-Wentrup FA. Antibody therapies for lymphoma in children. Cochrane Database Syst Rev 2016;19:CD0111181.
   Google Scholar